绝对淋巴细胞计数预测免疫联合放疗患者的远隔效应与结局
基于3项机构内1/2期试验的153例接受免疫治疗联合放疗患者数据,分析放疗后绝对淋巴细胞计数(ALC)与远隔效应的关系。多变量线性回归显示放疗后ALC与远隔效应相关(P < .001);放疗后ALC高于中位值者远隔效应率为34.2%,低于中位值者为3.9%(P < .0001)。Cox多变量分析确认较低的放疗后ALC与较差的无进展生存(P = .009)和总生存(P = .026)相关。
要点
- 放疗后ALC高于中位值者远隔效应率34.2%,低于中位值者仅3.9%(P < .0001)。
- 放疗前ALC高于中位值者远隔效应率30.3%,低于中位值者7.8%(P = .0004)。
- 较低的放疗后ALC与较差的无进展生存(P = .009)和总生存(P = .026)相关。
核心结论
- 放疗后ALC作为连续变量可能影响远隔效应的发生,进而影响接受放疗联合免疫治疗患者的预后。
研究设计与样本
- 利用3项机构内1/2期试验数据,纳入接受放疗联合免疫治疗且至少有一个未照射非连续病灶可评估远隔效应的患者。
- 共153例患者符合标准,中位随访21.1个月。
主要发现
- 最常见肿瘤类型为非小细胞肺癌(n = 62)、小细胞肺癌(n = 25)、头颈癌(n = 16)和肾细胞癌(n = 13)。
- 免疫治疗包括伊匹木单抗(n = 98)和帕博利珠单抗(n = 55)。
- 多变量线性回归显示放疗后ALC作为连续变量与远隔效应相关(P < .001)。
- 放疗后ALC高于中位值者远隔效应率为34.2%,低于中位值者为3.9%(P < .0001);放疗前ALC对应为30.3% vs 7.8%(P = .0004)。
- Cox多变量分析确认较低的放疗后ALC与较差的无进展生存(P = .009)和总生存(P = .026)相关。
关键数值与推荐
- 远隔效应定义为最佳Response Evaluation Criteria in Solid Tumors疗效。
- 放疗后ALC高于中位值者远隔效应率34.2%,低于中位值者3.9%(P < .0001)。
- 放疗前ALC高于中位值者远隔效应率30.3%,低于中位值者7.8%(P = .0004)。
临床怎么用
- 该假设生成性发现提示监测ALC的重要性,以及治疗性调控ALC以诱导远隔效应的潜在可能。
局限性
- 该假设生成性发现需要额外数据进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Research to elucidate predictive factors of the abscopal effect is an essential first step toward potentially modifying these factors to increase the incidence of systemic antitumor effects. This study, using data from 3 institutional phase 1/2 trials, examined the predictive capacity of recorded parameters in patients undergoing combined radiation therapy (RT) and immunotherapy and explored outcomes based on those predictive factors. METHODS AND MATERIALS: All patients underwent combined immunotherapy and RT and had at least 1 nonirradiated noncontiguous lesion to evaluate out-of-field (abscopal) responses, defined as the best Response Evaluation Criteria in Solid Tumors response. RESULTS: Altogether, 153 patients met study criteria, and the median follow-up was 21.1 months. The most common cancer types were non-small cell lung carcinoma (n = 62), small cell lung carcinoma (n = 25), head and neck cancers (n = 16), and renal cell carcinoma (n = 13). Immunotherapies included ipilimumab (n = 98) and pembrolizumab (n = 55). Multivariable linear regression indicated that post-RT absolute lymphocyte count (ALC), when analyzed as a continuous variable, correlated with abscopal responses (P < .001). For post-RT ALC, the abscopal response rate was 34.2% in the cohort with ALC higher than the median value, compared with 3.9% in patients with ALC lower than the median (P < .0001). Corresponding figures for pre-RT ALC were 30.3% versus 7.8%, respectively (P = .0004). Cox multivariate analysis confirmed that lower post-RT ALC also associated with poorer progression-free survival (P = .009) and overall survival (P = .026). CONCLUSIONS: Lymphopenia, measured as the continuous variable of post-RT ALC, may affect the occurrence of abscopal responses and thus influence prognosis in patients treated with RT and immunotherapy. Although this hypothesis-generating finding requires corroboration by additional data, it suggests the importance of ALC monitoring and the potential of therapeutic manipulation of this parameter to induce abscopal effects.
引用
- Chen D, Verma V, Patel RR, et al. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020. PMID: 32036004. doi:10.1016/j.ijrobp.2020.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。